Publications

2025

• Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study

  Severine Vermeire, Josianne Nitcheu, Paul Gineste, Aurélien Flatres, Julien Santo, Didier Scherrer, Laurent Peyrin-Biroulet, Parambir S Dulai, Silvio Danese, Marla Dubinsky, Herbert Tilg, Britta Siegmund, Tadakazu Hisamatsu, Kejia Shan, Christopher J Rabbat, Bruce E Sands
  J Crohns Colitis.2025;19(5):jjaf074.

2023

• Impact of obefazimod on viral persistence, inflammation, and immune activation in people with human immunodeficiency virus on suppressive antiretroviral therapy

  Silvia Bernal, Maria C Puertas, Sara Morón-López, Ross D Cranston, Víctor Urrea, Judith Dalmau, María Salgado, Cristina Gálvez, Itziar Erkizia, Ian McGowan, Didier Scherrer, Boris Revollo, Guillem Sirera, José Ramón Santos, Bonaventura Clotet, Roger Paredes, Javier Martinez-Picado
  J Infect Dis.2023;228(9):1280-1291.

• Obefazimod: a first-in-class drug for the treatment of ulcerative colitis

  Séverine Vermeire, Virginia Solitano, Laurent Peyrin-Biroulet, Herbert Tilg, Silvio Danese, Hartmut Ehrlich, Didier Scherrer, Paul Gineste, Laurence d’Agay, Bruce E Sands
  J Crohns Colitis.2023;17(10):1689-1697.

• ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

  Pedro Giavina-Bianchi, Eric Cua, Karine Risso, Véronique Mondain, Anaïs Vissian, Cécile Joie, Philippe Pouletty, Paul Gineste, Hartmut J Ehrlich, Jorge Kalil
  J Allergy Clin Immunol Glob.2023;2(4):100140.

• ABX464 (obefazimod) upregulates miR124 to reduce proinflammatory markers in inflammatory bowel diseases

  Cécile Apolit, Noëlie Campos, Audrey Vautrin, Christina Begon-Pescia, Laure Lapasset, Didier Scherrer, Paul Gineste, Hartmut Ehrlich, Aude Garcel, Julien Santo, Jamal Tazi
  Clin Transl Gastroenterol.2023;14(4):e00560.

2022

• ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

  Severine Vermeire, Bruce E Sands, Herbert Tilg, Zsolt Tulassay, Radoslaw Kempinski, Silvio Danese, Ivan Bunganič, Josianne Nitcheu, Julien Santo, Didier Scherrer, Sophie Biguenet, Hartmut J Ehrlich, Jean-Marc Steens, Paul Gineste, William J Sandborn
  Lancet Gastroenterol Hepatol.2022;7(11):1024-1035.

• Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

  Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
  Ann Rheum Dis.2022;81(8):1076-1084.

2021

• Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase IIa trial

  Séverine Vermeire, Xavier Hébuterne, Herbert Tilg, Gert De Hertogh, Paul Gineste, Jean-Marc Steens; ABX464 Investigators
  Gastroenterology.2021;160(7):2595-2598.e3.

• Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases

  Jamal Tazi, Christina Begon-Pescia, Noëlie Campos, Cécile Apolit, Aude Garcel, Didier Scherrer
  Drug Discov Today.2021;26(4):1030-1039.

2019

• Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing

  Audrey Vautrin, Laurent Manchon, Aude Garcel, Noëlie Campos, Laure Lapasset, Abdelhamid Mahdi Laaref, Roman Bruno, Marie Gislard, Emeric Dubois, Didier Scherrer, Hartmut J Ehrlich, Jamal Tazi
  Sci Rep.2019;9(1):792.

2017

• The anti-Hiv candidate Abx464 dampens intestinal inflammation by triggering Il-22 production in activated macrophages

  Karim Chebli, Laura Papon, Conception Paul, Aude Garcel, Noëlie Campos, Didier Scherrer, Hartmut J Ehrlich, Michael Hahne, Jamal Tazi
  Sci Rep.2017;7(1):4860.

• Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects

  Didier Scherrer, Regine Rouzier, P Noel Barrett, Jean-Marc Steens, Paul Gineste, Robert L Murphy, Jamal Tazi, Hartmut J Ehrlich
  J Antimicrob Chemother.2017;72(3):820-828.

2016

• Randomized trial of food effect on pharmacokinetic parameters of ABX464 administered orally to healthy male subjects

  Didier Scherrer, Regine Rouzier, Marine Cardona, P Noel Barrett, Jean-Marc Steens, Paul Gineste, Robert L Murphy, Jamal Tazi, Hartmut J Ehrlich
  Antimicrob Agents Chemother.2016;61(1):e012288-16.

2015

• Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis

  Noëlie Campos, Renier Myburgh, Aude Garcel, Audrey Vautrin, Laure Lapasset, Erika Schläpfer Nadal, Florence Mahuteau-Betzer, Romain Najman, Pauline Fornarelli, Katjana Tantale, Eugénia Basyuk, Martial Séveno, Julian P Venables, Bernard Pau, Edouard Bertrand, Mark A Wainberg, Roberto F Speck, Didier Scherrer, Jamal Tazi
  Retrovirology.2015;12:30.